Business / Finance

RSS

TVM Capital Healthcare Partners signs affiliation with Joslin Diabetes Center

TVM Capital Healthcare Partners, the region's first private equity firm dedicated exclusively to the healthcare sector, has signed an affiliation with Joslin Diabetes Center.

17 Mar 2014

Almost Family agrees to acquire Caldwell Medical Center's Medicare-certified home health agency

Almost Family, Inc., today announced that it has entered into an agreement to acquire the assets of the Medicare-certified home health agency owned by Caldwell Medical Center located in Princeton, Kentucky.

16 Mar 2014

Derma Sciences' net sales increase 3% to $20.7 million in fourth quarter 2013

Derma Sciences, Inc., a tissue regeneration and burn care company focused on advanced wound care, today reported financial and operating results for the three months and year ended December 31, 2013.

14 Mar 2014

Bruker releases application note for detection of pharmaceutical and personal care products in water using EVOQ LC-MS/MS

Bruker has released an application note detailing a simple and convenient method for the quantification of trace pharmaceutical and personal care products (PPCPs) in clean water, using Bruker’s EVOQ triple quadrupole liquid chromatography mass spectrometer (LC-MS/MS). PPCPs are products used for personal health or cosmetic reasons.

13 Mar 2014

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma, Inc. today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

SAGE Therapeutics announces completion of $38 million Series C financing

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, today announced the successful completion of a $38 million Series C financing. OrbiMed Advisors, LLC, EcoR1 Capital Management, Foresite Capital Management and two undisclosed blue chip public investment funds joined existing investors Third Rock Ventures and ARCH Venture Partners.

13 Mar 2014

Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the fourth quarter ended December 31, 2013, as well as recent business updates.

13 Mar 2014

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Knopp Biosciences LLC today announced a second collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to investigate the eosinophil-lowering effects of the investigational drug dexpramipexole.

13 Mar 2014

Quad-C Management makes five investments in the last 15 months

Quad-C Management, a leading middle market private equity firm, today announced the firm has made five investments in the last 15 months, including four new investments and one add-on investment to a current portfolio company.

13 Mar 2014

CRO services division of Galapagos to be acquired by Charles River Laboratories

Charles River Laboratories International, Inc. announced today that it has entered into a definitive agreement to acquire the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus.

13 Mar 2014

Galmed Pharmaceuticals prices initial public offering of 2,837,400 shares

Galmed Pharmaceuticals Ltd. ("Galmed") today announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public offering price of $13.50 per share, before underwriting discounts and commissions.

13 Mar 2014

Quintiles prices secondary public offering of 15M shares of common stock

Quintiles today announced the pricing of a secondary public offering of 15 million shares of its common stock by certain of its shareholders at a price to the public of $52.00 per share.

13 Mar 2014

RTI Surgical launches 2 new biological solutions at AAOS annual meeting in New Orleans

RTI Surgical Inc., a leading global surgical implant company, is launching two new biological solutions at the American Academy of Orthopaedic Surgeons annual meeting in New Orleans this week. NanOss Bioactive 3D, a synthetic three dimensional bioscaffold which supports bone formation, and map3™ Cellular Allogeneic Bone Graft, an implant that contains the three essential elements needed to generate and maintain new bone, will be introduced at the RTI Surgical exhibit at booth 5937 (Hall H) during the AAOS meeting.

12 Mar 2014

Respicardia receives Best Innovation of 2014 award from CRT and CV Pipeline for remedē System

Respicardia, Inc., a developer of implantable therapies to improve respiratory and cardiovascular health, announced that it has been awarded the Best Innovation of 2014 from Cardiovascular Research Technologies (CRT) and CV Pipeline for the remedē System, the first and only implantable device for the treatment of central sleep apnea.

12 Mar 2014

iCAD prices underwritten public offering of 2,400,000 shares of common stock

iCAD, Inc. ("iCAD"), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer, today announced it has priced a registered firm commitment underwritten public offering of 2,400,000 shares of its common stock at a price to public of $11.00 per share.

12 Mar 2014

Amedisys' net service revenue decreases 13.7% to $303.5 million in Q4 2013

Amedisys, Inc., a leading home health and hospice company, today reported its financial results for the fourth quarter and year ended December 31, 2013.

12 Mar 2014

Precision and Agrivida enter into trait development collaboration based on precise gene modifications

Precision BioSciences and Agrivida revealed today that they have entered into a trait development collaboration based on precise gene modifications made possible by Precision's Directed Nuclease Editor (DNE) Technology.

12 Mar 2014